QURE Stock Overview
Develops treatments for patients suffering from rare and other devastating diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.18 |
| 52 Week High | US$19.18 |
| 52 Week Low | US$3.73 |
| Beta | 0.42 |
| 1 Month Change | 13.71% |
| 3 Month Change | -7.44% |
| 1 Year Change | 223.01% |
| 3 Year Change | -10.08% |
| 5 Year Change | -76.76% |
| Change since IPO | -2.94% |
Recent News & Updates
Recent updates
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
Apr 19uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
Feb 20uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Dec 10Is There An Opportunity With uniQure N.V.'s (NASDAQ:QURE) 39% Undervaluation?
Dec 07
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Oct 21uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08Shareholder Returns
| QURE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.7% | 4.4% | 7.0% |
| 1Y | 223.0% | -5.0% | 7.5% |
Return vs Industry: QURE exceeded the US Biotechs industry which returned -4.1% over the past year.
Return vs Market: QURE exceeded the US Market which returned 7.8% over the past year.
Price Volatility
| QURE volatility | |
|---|---|
| QURE Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: QURE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QURE's weekly volatility has decreased from 24% to 17% over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 209 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.
uniQure N.V. Fundamentals Summary
| QURE fundamental statistics | |
|---|---|
| Market cap | US$766.81m |
| Earnings (TTM) | -US$239.56m |
| Revenue (TTM) | US$27.12m |
28.3x
P/S Ratio-3.2x
P/E RatioIs QURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QURE income statement (TTM) | |
|---|---|
| Revenue | US$27.12m |
| Cost of Revenue | US$159.96m |
| Gross Profit | -US$132.84m |
| Other Expenses | US$106.72m |
| Earnings | -US$239.56m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.43 |
| Gross Margin | -489.84% |
| Net Profit Margin | -883.35% |
| Debt/Equity Ratio | -7,201.6% |
How did QURE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 03:52 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
uniQure N.V. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Madhu Kumar | B. Riley Securities, Inc. |